Brisbane, Australia:
- Launched in Spain and Colombia in 2020, myBIOME is an revolutionary gut microbiome examination based mostly on expertise developed by Microba’s main researchers within the subject of microbiome evaluation.
- The mixture of modern complete metagenomic sequencing and evidence- based mostly reporting supplies exact imaging of the gut microbiome.
- myBIOME supplies a complete evaluation of the composition of a person’s gut microbiome and its purposeful potential to ship personalised therapy or vitamin suggestions.
- Consumers and healthcare professionals alike profit from the great gut microbiome evaluation that myBIOME supplies to detect the reason for a broad vary of well being complaints.
- SYNLAB and Microba are actually extending the providing to wider distribution throughout Europe and Latin America.
SYNLAB, the chief in medical diagnostic companies and specialty testing in Europe, and Microba Life Sciences (Microba), a worldwide chief within the evaluation of advanced gut microbiomes, have expanded their strategic agreement to broaden geographic and market availability of the microbiome test myBIOME throughout Europe and Latin America.
Responding to the success on the Spanish and Colombian markets and the rising demand for personalised precision diagnostics, the test can be rolled out for additional distribution through healthcare suppliers in addition to direct-to-consumer channels.
“Imbalances in the gut microbiome composition, distribution and activity have a direct health impact and are associated with chronic illness including gastrointestinal, inflammatory, metabolic, neurological and cardiovascular conditions,” says Michael Morris, Head of Genetics at SYNLAB Switzerland. “myBIOME is the most complete and accurate metagenomic sequencing test available on the market today, allowing for a comprehensive, highly differentiated and actionable analysis of an individual’s gut microbiome.”
Through NGS (Next-Generation Sequencing), myBIOME analyses all of the genetic materials (DNA) in a stool pattern, permitting a extremely delicate, high-resolution panel of the microorganisms that make it up.
Applying game-changing metagenomic expertise developed by Microba, myBIOME detects all kinds of microorganisms (micro organism, archaea, fungi, protists), identifies the precise species and characterises new species. Based on the purposeful potential decided by analysing the microbial genes current, the test report delivers a personalised evaluation and dietary suggestions to enhance affected person well being and high quality of life.
“SYNLAB is committed to offering medical excellence around the globe and I am excited that now, more customers and patients will benefit from this reliable tool,” says Marta Llopis, myBIOME/ Microbiome Specialist at SYNLAB Group. “In many cases, myBIOME has pinpointed the origin of a variety of diffuse symptoms by linking them to a microbiome imbalance or for example an excessive presence of non-intestinal species. When found at high levels in the gut, these have been shown to cause disease.”
About SYNLAB
SYNLAB Group is the chief in medical diagnostic companies and specialty testing in Europe. The Group presents a full vary of revolutionary and dependable medical diagnostics to sufferers, practising docs, hospitals and clinics, governments and corporates. SYNLAB operates in 36 international locations throughout 4 continents and holds main positions in most markets, often reinforcing the power of its community by means of a confirmed acquisition technique. More than 30,000 staff, together with over 2,000 medical consultants, contribute to the Group’s success. SYNLAB carried out round 600 million laboratory checks and achieved revenues of €3.76 billion in 2021.
More data on myBIOME could be discovered at www.mybiome.well being
About Microba
Microba Life Sciences (ASX: MAP) is a precision microbiome firm pushed to enhance human well being. Through partnerships with main organisations, Microba is powering the invention of latest relationships between the microbiome, well being and illness for the event of latest well being options.
View supply model on businesswire.com: https://www.businesswire.com/news/home/20221027005459/en/